Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol cip haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol multi haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. seroflo ciphaler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include,? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. seroflo multihaler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. salplusf dpi 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

cipla europe nv - salmeterol xinafoato; fluticasona propionato - suspensiÓn para inhalaciÓn en envase a presiÓn - 25 microgramos/125 microgramos - salmeterol xinafoato 25 microgramos; fluticasona propionato 125 microgramos - salmeterol y fluticasona

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

cipla europe nv - salmeterol xinafoato; fluticasona propionato - suspensiÓn para inhalaciÓn en envase a presiÓn - 25 microgramos/250 microgramos - salmeterol xinafoato 25 microgramos; fluticasona propionato 250 microgramos - salmeterol y fluticasona

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

cipla europe nv - salmeterol xinafoato; fluticasona propionato - polvo para inhalaciÓn (unidosis) - 50 microgramos/250 microgramos/dosis - salmeterol xinafoato 50 microgramos; fluticasona propionato 250 microgramos - salmeterol y fluticasona

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

cipla europe nv - salmeterol xinafoato; fluticasona propionato - polvo para inhalaciÓn (unidosis) - 50 microgramos/500 microgramos/dosis - salmeterol xinafoato 50 microgramos; fluticasona propionato 500 microgramos - salmeterol y fluticasona

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

biogaran - salmétérol 25 microgrammes sous forme de : xinafoate de salmétérol; propionate de fluticasone 250 microgrammes - suspension - 25 microgrammes - pour une dose > salmétérol 25 microgrammes sous forme de : xinafoate de salmétérol > propionate de fluticasone 250 microgrammes - adrénergiques en association avec des corticoïdes ou d’autres médicaments à l’exclusion des anticholinergiques - classe pharmacothérapeutique : adrénergiques en association avec des corticoïdes ou d’autres médicaments à l’exclusion des anticholinergiques - code atc : r03ak06.propionate de fluticasone/salmeterol bgr est un médicament contenant deux principes actifs, le salmétérol et le propionate de fluticasone : le salmétérol est un bronchodilatateur de longue durée d’action. les bronchodilatateurs aident à garder les bronches ouvertes. cela permet de faciliter l’entrée et la sortie de l’air dans les poumons. l’effet dure au moins 12 heures. le propionate de fluticasone est un corticoïde qui diminue l’inflammation et l’irritation dans les poumons.votre médecin vous a prescrit ce médicament pour aider à prévenir certains troubles respiratoires tels que l’asthme.vous devez utiliser propionate de fluticasone/salmeterol bgr tous les jours comme indiqué par votre médecin. cela permettra de contrôler correctement votre asthme.propionate de fluticasone/salmeterol bgr permet d’éviter la survenue d’essoufflement et de sifflement. cependant, propionate de fluticasone/salmeterol bgr ne doit pas être utilisé lorsque vous avez une crise soudaine d’essoufflement ou de sifflement. dans ces cas, vous devez utiliser votre médicament bronchodilatateur dit « de secours » d’action rapide et de courte durée, comme le salbutamol. vous devez toujours avoir sur vous votre inhalateur dit « de secours » d’action rapide et de courte durée.